Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GW01-200 Tablets in Subjects With Advanced Tumors

NCT07629258 is registered in ClinicalTrials.gov with Groovy Medicine (Hangzhou) Ltd. as lead sponsor.

NCT NCT07629258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07629258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GW01-200 Tablets in Subjects With Advanced Tumors
Lead sponsor
Groovy Medicine (Hangzhou) Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 17, 2026
Completion date
June 30, 2029
Enrollment
100 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced tumors